Emboldened by Dupixent COPD win, Sanofi execs pitch leading immunology's next era
Since launching in 2017, Dupixent has racked up a range of approvals on its path to becoming Sanofi’s best-selling drug.
On Sunday, Sanofi and Regeneron highlighted another late-stage Dupixent success that could make it the first biologic medicine to treat COPD, or chronic obstructive pulmonary disease. Results were published in The New England Journal of Medicine and presented at the American Thoracic Society’s meeting in Washington.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.